Related Experiment Videos
[Atrial natriuretic peptide in chronic circulatory failure in patients with ischemic heart disease]
Vrachebnoe Delo
|September 1, 1990
Insights
Human precordial natriuretic peptide (alpha-HPNP) levels were studied in chronic ischemic heart disease patients. Higher alpha-HPNP may indicate its role in circulatory insufficiency progression.
Area of Science:
- Cardiology
- Biochemistry
- Pathophysiology
Background:
- Chronic ischemic heart disease (CIHD) is a significant cause of heart failure.
- Circulatory insufficiency is a common complication of CIHD.
- Natriuretic peptides are involved in cardiovascular homeostasis.
Purpose of the Study:
- To investigate the content of human precordial natriuretic peptide (alpha-HPNP) in patients with CIHD.
- To determine the relationship between alpha-HPNP levels and the stage of circulatory insufficiency in CIHD patients.
Main Methods:
- Blood samples were collected from 26 patients with CIHD.
- alpha-HPNP content was measured in these samples.
- Patients were categorized based on the stage of circulatory insufficiency.
Main Results:
- alpha-HPNP content varied among patients with different stages of circulatory insufficiency.
- A correlation was observed between alpha-HPNP levels and the severity of circulatory insufficiency.
Conclusions:
- alpha-HPNP may play a role in the pathogenesis of circulatory insufficiency in CIHD.
- The level of alpha-HPNP appears to be dependent on the stage of circulatory insufficiency.
Abstract:
The content of human precordial natriuretic peptide (alpha-HPNP) was examined in 26 patients suffering of chronic ischemic heart disease with different stages of circulatory insufficiency. It is suggested that alpha-HPNP participates in the pathogenesis of circulatory insufficiency in patients with chronic ischemic heart disease and depended on the stage of circulatory insufficiency.